Zevra Therapeutics Inc.
$ 10.61
-5.01%
05 Jun - close price
- Market Cap 627,211,000 USD
- Current Price $ 10.61
- High / Low $ 11.18 / 10.36
- Stock P/E 5.28
- Book Value 3.48
- EPS 2.01
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 1.01 %
- 52 Week High 13.16
- 52 Week Low 7.16
About
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Analyst Target Price
$23.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-09 | 2025-11-05 | 2025-08-12 | 2025-05-13 | 2025-03-11 | 2024-11-12 | 2024-08-13 | 2024-05-08 | 2024-03-28 | 2023-11-07 | 2023-08-14 |
| Reported EPS | 0.6 | 0.19 | -0.01 | -0.06 | -0.06 | -0.69 | -0.69 | -0.48 | -0.4 | -0.4 | -0.4 | -0.15 |
| Estimated EPS | 0.08 | 0.05 | -0.02 | 1.38 | -0.18 | -0.3986 | -0.41 | -0.44 | -0.48 | -0.27 | -0.3 | -0.34 |
| Surprise | 0.52 | 0.14 | 0.01 | -1.44 | 0.12 | -0.2914 | -0.28 | -0.04 | 0.08 | -0.13 | -0.1 | 0.19 |
| Surprise Percentage | 650% | 280% | 50% | -104.3478% | 66.6667% | -73.1059% | -68.2927% | -9.0909% | 16.6667% | -48.1481% | -33.3333% | 55.8824% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZVRA
2026-06-05 20:18:54
Zevra Therapeutics stockholders held their 2026 annual meeting on June 4, 2026, electing two Class II directors and ratifying Ernst & Young LLP as the independent auditor. A proposal to declassify the board failed to pass, as it did not receive the required more-than 66 2/3% of outstanding shares for approval, thus maintaining the current classified board structure. This outcome means that only a portion of the board directors will be up for election each year, providing resistance against hostile takeovers but potentially slowing strategic changes.
2026-06-04 17:40:03
This article provides a technical analysis and stock price forecast for Zevra Therapeutics Inc (ZVRA). Based on a proprietary AI analysis aggregating 11 technical signals, the current sentiment for ZVRA is a "Strong Buy." The analysis details momentum indicators, support and resistance levels, and various moving averages, all of which generally support a bullish outlook for the stock.
2026-05-30 21:39:28
This page provides comprehensive stock information for Zevra Therapeutics Inc (ZVRA), including its current price, financial metrics, performance indicators, and recent news and analyst ratings. It details insider transactions and company executives.
2026-05-30 06:40:10
This article provides a detailed overview of Zevra Therapeutics, Inc. (ZVRA) stock performance, current trading price, and key market data. It highlights the company's strong performance over the past month and year, its classification within the PHARMACEUTICAL PREPARATIONS sector, and offers guidance on how to buy its stock on MEXC. The article also includes comprehensive FAQ addressing common investor questions about ZVRA.
2026-05-29 20:42:00
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) price action, noting divergent sentiment and an ongoing breakout with no resistance levels above the current price. It provides AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for tactical trading. The analysis also includes multi-timeframe signal analysis indicating strong near-term potential, weak mid-term, and neutral long-term sentiment.
2026-05-29 20:40:13
Zevra Therapeutics announced the grant of 33,000 stock options to four new employees under its 2023 Employment Inducement Award Plan, in line with Nasdaq Rule 5635(c)(4). These options vest over four years, with 25% vesting after the first year and the remainder in three equal annual installments. This routine HR announcement follows a period of strong financial performance for Zevra, including significant revenue growth and debt repayment.
